Researchmoz added Most up-to-date research on "Antibacterial Therapies Drug Development Pipeline Review, 2017" to its huge collection of research reports.
The antibacterial drug market covers the drugs used in the prophylaxis and treatment of bacterial infections. With a growing global concern over antimicrobial resistance and its progressive growth, there is a pronounced need for innovation within this market.
To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1049122
There are over 1400 products in active development in the antibacterial drug market, with the majority of products being small molecules. Vaccines are also well established within the market, and accounts for approximately 25% of the pipeline.
Currently, drugs for the prevention of bacterial infections are typically vaccines which help to train the bodys immune system to fight off bacterial infections caused by specific bacterial strains. However, several prophylactic monoclonal antibodies are now in the pipeline and may impact the market in the near future.
Drugs for the treatment of bacterial infections are slightly more varied. Most common are beta-lactam antibiotics, such as penicillin, and protein synthesis inhibitors. However, bacterial resistance has reduced the efficacy of many of these drugs. As a result the pipeline includes a variety of new-generation protein synthesis inhibitors and beta-lactam/beta-lactamase inhibitor combination drugs, which are active against currently hard to treat bacterial strains.
The report provides comprehensive information on the pipeline development landscape for Pneumonia, Methicillin-resistant staphylococcus aureus (MRSA) and Tuberculosis, from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.
Scope
Which companies are the most active within the pipeline for antibacterial drugs.
Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication.
To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies.
What are the most important R&D milestones and data publications to have happened in this disease area.
Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/antibacterial-therapies-drug-development-pipeline-review-2017-report.html/toc
Reasons to buy
Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Table of Contents
GBI Research Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 6
List of Figures 16
Introduction 20
GBI Research Report Coverage 20
Tuberculosis Overview 20
Pneumonia 20
Methicillin-Resistant Staphylococcus aureus (MRSA) 21
Therapeutics Development 22
Tuberculosis 22
Pneumonia 24
Methicillin-Resistant Staphylococcus aureus (MRSA) 33
Therapeutics under Development by Companies 38
Tuberculosis 38
Pneumonia 41
Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1049122
Methicillin-Resistant Staphylococcus aureus (MRSA) 50
Therapeutics under Investigation by Universities/Institutes 55
Tuberculosis 55
Pneumonia 57
Methicillin-Resistant Staphylococcus aureus (MRSA) 60
Pipeline Products Glance 62
Tuberculosis 62
Pneumonia 65
Methicillin-Resistant Staphylococcus aureus (MRSA) 79
Products under Development by Companies 83
Tuberculosis 83
Continue...
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on @ https://marketsizeinfo.blogspot.in/
The antibacterial drug market covers the drugs used in the prophylaxis and treatment of bacterial infections. With a growing global concern over antimicrobial resistance and its progressive growth, there is a pronounced need for innovation within this market.
To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1049122
There are over 1400 products in active development in the antibacterial drug market, with the majority of products being small molecules. Vaccines are also well established within the market, and accounts for approximately 25% of the pipeline.
Currently, drugs for the prevention of bacterial infections are typically vaccines which help to train the bodys immune system to fight off bacterial infections caused by specific bacterial strains. However, several prophylactic monoclonal antibodies are now in the pipeline and may impact the market in the near future.
Drugs for the treatment of bacterial infections are slightly more varied. Most common are beta-lactam antibiotics, such as penicillin, and protein synthesis inhibitors. However, bacterial resistance has reduced the efficacy of many of these drugs. As a result the pipeline includes a variety of new-generation protein synthesis inhibitors and beta-lactam/beta-lactamase inhibitor combination drugs, which are active against currently hard to treat bacterial strains.
The report provides comprehensive information on the pipeline development landscape for Pneumonia, Methicillin-resistant staphylococcus aureus (MRSA) and Tuberculosis, from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.
Scope
Which companies are the most active within the pipeline for antibacterial drugs.
Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication.
To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies.
What are the most important R&D milestones and data publications to have happened in this disease area.
Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/antibacterial-therapies-drug-development-pipeline-review-2017-report.html/toc
Reasons to buy
Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Table of Contents
GBI Research Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 6
List of Figures 16
Introduction 20
GBI Research Report Coverage 20
Tuberculosis Overview 20
Pneumonia 20
Methicillin-Resistant Staphylococcus aureus (MRSA) 21
Therapeutics Development 22
Tuberculosis 22
Pneumonia 24
Methicillin-Resistant Staphylococcus aureus (MRSA) 33
Therapeutics under Development by Companies 38
Tuberculosis 38
Pneumonia 41
Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1049122
Methicillin-Resistant Staphylococcus aureus (MRSA) 50
Therapeutics under Investigation by Universities/Institutes 55
Tuberculosis 55
Pneumonia 57
Methicillin-Resistant Staphylococcus aureus (MRSA) 60
Pipeline Products Glance 62
Tuberculosis 62
Pneumonia 65
Methicillin-Resistant Staphylococcus aureus (MRSA) 79
Products under Development by Companies 83
Tuberculosis 83
Continue...
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on @ https://marketsizeinfo.blogspot.in/
No comments:
Post a Comment